About Revance Therapeutics, Inc
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California. Address: 1222 Demonbreun Street, Newark, CA, United States, 37203
Revance Therapeutics, Inc News and around…
Latest news about Revance Therapeutics, Inc (RVNC) common stock and company :
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $60.60 per unit.
Multiple insiders secured a larger position in Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares over the last 12...
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to ...
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer ...
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per ...
Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Revance Therapeutics Inc (RVNC), where a total of 6,325 contracts have traded so far, representing approximately 632,500 underlying shares. That amounts to about 106% of RVNC's average daily trading volume over the past month of 596,935 shares..
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus WHO Backs Pfizer's Oral ...
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug ...
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $65.19 per unit.
Investors can buy low cost index fund if they want to receive the average market return. But in any diversified...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mr Cooper Group Inc (COOP), where a total volume of 44,553 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 521.2% of COOP's average daily trading volume over the past month, of 854,850 shares..
Biopharma stocks outperformed the broader market in the week endingApril 2, thereby recouping the losses from the previous week. ...
Revance To Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 AAN Annual Meeting
Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in US Foods Holding Corp (USFD), where a total of 32,414 contracts have traded so far, representing approximately 3.2 million underlying shares. That amounts to about 139.6% of USFD's average daily trading volume over the past month of 2.3 million shares..
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value ...
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA
Revance to Participate in the Cowen 42nd Annual Health Care Conference
Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what ...
Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its ...
A publicly traded biotech company that moved headquarters from California to Nashville is doubling its jobs commitment to about 260 people, and doubling its state incentives as well. State officials on Wednesday approved the extra funding for Revance Therapeutics Inc. (Nasdaq: RVNC), as well as three other Greater Nashville jobs announcements.
Revance Therapeutics, Inc (RVNC) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
